Roche's Polivy ADC Is Approved As Another New Option For R/R DLBCL

The first-in-class anti-CD79b antibody-drug conjugate received a swift accelerated approval by the US FDA based on the results of a Phase Ib/II trial, for the same setting as CAR-T agents.

A young man' hand is displaying a thumbs up, indicating that he likes or approves of something - Image

Roche is launching Polivy (polatuzumab vedotin-piiq) for the treatment of adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) in the US with an aim to move the first-in-class antibody-drug conjugate (ADC) into the front-line setting.

The anti-CD79b ADC was granted an accelerated approval from the FDA on 10 June based on the results of a...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from New Products

More from Scrip